Amgen, the world's largest biotech company by revenue, and deCODE, based in Reykjavik, Iceland, announced the all-cash deal Monday. DeCODE, founded in 1996, has discovered genetic risk factors for ...

Its lead therapeutic programs, which leverage the company's expertise in chemistry and structural biology, include DG041, an antiplatelet compound being developed for the prevention of arterial ...

REYKJAVIK, Iceland, Jan. 29, 2024 /PRNewswire/ -- Scientists at deCODE genetics, a subsidiary of Amgen, and their collaborators from Iceland, Denmark, and the USA published a study today in Nature ...

REYKJAVIK, Iceland, June 24, 2020 /PRNewswire/ -- Scientists at deCODE genetics, a subsidiary of Amgen, and their collaborators from the Icelandic healthcare system, University of Iceland and the ...

For 25 years, Iceland’s deCODE Genetics has been one of the most powerful and prolific producers and analyzers of human genomic sequence data. Founded by neurologist Kári Stefánsson, deCODE has ...

Amgen Inc. on Monday said that it has agreed to buy Decode Genetics, an Icelandic company that can help Amgen develop personalized drug therapies, for $415 million. The Reykjavik human genetics ...

Scientists at deCODE genetics, a subsidiary of Amgen, have been focusing on actionable genotypes detected in the Icelandic population. Recently, the researchers found that approximately 1 in 25 ...

deCODE close to broke Icelandic biotech deCODE Genetics may become another casualty of tough economic times.

Reykjavik, ICELAND, October 8, 2008 – deCODE genetics (Nasdaq:DCGN) today announced the launch of deCODE BreastCancer™, a new tool for assessing risk of the common forms of breast cancer. For the ...

Amgen Inc. agreed to acquire Iceland-based deCODE genetics Inc., which identifies genetic risk factors for dozens of diseases, for about $415 million. Amgen President and Chief Executive Robert A.